Diagnostic significance of complete blood count in cardiovascular patients; Samara State Medical University

This article discusses the relationship between parameters of complete blood count (CBC) and cardiovascular diseases (CVD). The main advantages of CBC over other methods of CVD diagnostics are low cost and wide availability. At the same time, the low specificity of CBC is an important disadvantage, limiting its diagnostic value.

After analyzing the results of numerous clinical studies, we concluded that the most important CBC are red cell distribution width, mean platelet volume, total leukocyte count, neutrophil to lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte to high-density lipoprotein ratio. We discuss the diagnostic value of each of the above indicators in CVD. Careful attention to these parameters by clinicians can, to a certain extent, improve the therapeutic and diagnostic process in patients with CVD.

1. Chaulin AM, Karslyan LS, Grigoriyeva EV, et al. Clinical and Diagnostic Value of Cardiac Markers in Human Biological Fluids. Kardiologiia. 2019;59(11):66-75. (In Russ.) doi:10.18087/cardio.2019.11.n414.

2. Alieva AM, Nikitin IG, Starodubova AV, et al. Diagnostic and Prognostic Value of Natriuretic Peptides in Cardiac Patients. Lechebnoye delo. 2016;3:78-84. (In Russ.)

3. Chaulin AM, Duplyakov DV. Increased cardiac troponins, not associated with acute coronary syndrome. Part 1. Cardiology: News, Opinions, Training. 2019;7(2):13-23. (In Russ.). doi:10.24411/2309-1908-2019-12002.

4. Kremneva LV, Suplotov SN, Shalaev SV. Modern high-sensitive troponin diagnostic methods in assessment of myocardial ischemia and prognostical value for chronic coronary heart disease. Russian Journal of Cardiology. 2017;(3):160-164. (In Russ.) doi:10.15829/1560-4071-2017-3-160-164.

5. Dixon LR. The complete blood count: physiologic basis and clinical usage. J Perinatal Neonatal Nurs. 1997;11(3):1-18. doi:10.1097/00005237-199712000-00003.

6. Anderson JL, Ronnow BS, Horne BD, et al. Usefulness of a complete blood count-derived risk score to predict incident mortality in patients with suspected cardiovascular disease. Am J Cardiol. 2007;99(2):169-74. doi:10.1016/j.amjcard.2006.08.015.

7. Blindar VN, Zubrikhina GN, Matveeva II, Kushlinsky NE. Hematological research methods. The clinical significance of blood counts. M.: Publishing House Medical Information Agency LLC, 2013. p. 96. (In Russ.) ISBN: 978-5-9986-0135-4.

8. Novikova IA, Khoduleva SA. Clinical and laboratory hematology. Minsk “Higher School Publishing House”, 2013. p. 445 (In Russ.) ISBN: 978-985-06-2226-6.

9. Chen PC, Sung FC, Chien KL, et al. Red blood cell distribution width and risk of cardiovascular events and mortality in a community cohort in Taiwan. Am J Epidemiol. 2009;171(2):214-20. doi:10.1093/aje/kwp360.

10. Wen Y. High red blood cell distribution width is closely associated with risk of carotid artery atherosclerosis in patients with hypertension. Exp Clin Cardiol. 2010;15(3):37-40.

11. Walters MC, Abelson HT. Interpretation of the complete blood count. Pediatr Clin North Am. 1996;43(3):599-622. doi:10.1016/s0031-3955(05)70424-7.

12. Sharma R, Agrawal VV. The relationship between red blood cell distribution width (RDW CV) and C reactive protein (CRP) with the clinical outcomes in non-ST elevation myocardial infarction and unstable angina pectoris: a 6 months follow up study. Int Cardiovasc Forum J. 2015;2:27-31. doi:10.17987/icfj.v2i1.68.

13. Al-Kindi SG, Refaat M, Jayyousi A, et al. Red cell distribution width is associated with all-cause and cardiovascular mortality in patients with diabetes. Biomed Res Int. 2017:5843702. doi:10.1155/2017/5843702.

14. Ozcan F, Turak O, Durak A, et al. Red cell distribution width and inflammation in patients with nondipper hypertension. Blood Press. 2013;22(2):80-5. doi:10.3109/08037051.2012.707336.

15. Borne Y, Smith JG, Melander O, et al. Red cell distribution width and risk for first hospitalization due to heart failure: a population-based cohort study. Eur J Heart Fail. 2011;13(12):1355-61. doi:10.1093/eurjhf/hfr127.

16. Lappegard J, Ellingsen TS, Vik A, et al. 2015. Red Cell Distribution Width and Carotid Atherosclerosis Progression: The Troms0 Study. Thromb Haemost. 2015;113(3):649-54. doi:10.1160/TH14-07-0606.

17. Alshawabkeh L, Rajpal S, Landzberg MJ, et al. Relationship of Red Cell Distribution Width to Adverse Outcomes in Adults With Congenital Heart Disease (from the Boston Adult Congenital Heart Biobank). Am J Cardiol. 2018;122(9):1557-64. doi:10.1016/j.amjcard.2018.07.019.

18. Abrahan LL 4th, Ramos JDA, Cunanan EL, et al. Red Cell Distribution Width and Mortality in Patients With Acute Coronary Syndrome: A Meta-Analysis on Prognosis. Cardiol Res. 2018;9(3):144-52. doi:10.14740/cr732w.

19. van Kimmenade RR, Mohammed AA, Uthamalingam S, et al. Red blood cell distribution width and 1-year mortality in acute heart failure. Eur J Heart Fail. 2010;12(2):129-36. doi:10.1093/eurjhf/hfp179.

20. Erhart S, Beer JH, Reinhart WH. Influence of aspirin on platelet count and volume in humans. Acta Haematol. 1999;101(3):140-4. doi:10.1159/000040940.

21. Demirkol S, Balta S, Unlu M, et al. Evaluation of the mean platelet volume in patients with cardiac syndrome X. Clinics (Sao Paulo). 2012;67(9):1019-22. doi:10.6061/clinics/2012(09)06.

22. Braekkan S, Mathiesen EB, Njolstad I, et al. Mean platelet volume is a risk factor for venous thromboembolism: the Troms0 study. J Thromb Haemost. 2010;8(1):157-62. doi:10.1111/j.1538-7836.2009.03498.x.

23. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract. 2009;63(10):1509-15. doi:10.1111/j.1742-1241.2009.02070.x.

24. Díaz JM, Boietti BR, Vazquez FJ, et al. Mean platelet volume as a prognostic factor for venous thromboembolic disease. Rev Med Chil. 2019;147(2):145-52. doi:10.4067/s0034-98872019000200145.

25. Kostrubiec M, Eabyk A, Pedowska-W+oszek J, et al. Mean platelet volume predicts early death in acute pulmonary embolism. Heart (British Cardiac Society). 2010;96(6):460-5. doi:10.1136/hrt.2009.180489.

26. Assiri AS, Jamil AM, Mahfouz AA, et al. Diagnostic importance of platelet parameters in patients with acute coronary syndrome admitted to a tertiary care hospital in southwest region, Saudi Arabia. J Saudi Heart Assoc. 2012;24(1):17-21. doi:101016/j.jsha.2011.08.004.

27. Nunez J, Minana G, Bodi V, et al. Low lymphocyte count and cardiovascular diseases. Curr Med Chem. 2011;18(21):3226-33. doi:10.2174/092986711796391633.

28. Slavka G, Perkmann T, Haslacher H, et al. Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler Thromb Vasc Biol. 2011;31(5):1215-8. doi:10.1161/ATVBAHA.110.221788.

29. Wada H, Dohi T, Miyauchi K, et al. Mean platelet volume and long-term cardiovascular outcomes in patients with stable coronary artery disease. Atherosclerosis. 2018;277:108-112. doi:10.1016/j.atherosclerosis.2018.08.048.

30. Lin WY, Lu X, Fan FJ, et al. Predictive Effect of Mean Platelet Volume in Patients with Portal Vein Thrombosis: A Meta-analysis of Case-control Studies. Curr Med Sci. 2018;38(4):575-81. doi:10.1007/s11596-018-1916-z.

31. Horne BD, Anderson JL, John JM, et al. Which white blood cell subtypes predict increased cardiovascular risk? J Am Coll Cardiol. 2005;45(10):1638-43. doi:10.1016/j.jacc.2005.02.054.

32. Karino S, Willcox BJ, Fong K, et al. Total and differential white blood cell counts predict eight-year incident coronary heart disease in elderly Japanese-American men: the Honolulu Heart Program. Atherosclerosis. 2015;238(2):153-8. doi:10.1016/j.atherosclerosis.2014.12.003.

33. Barron HV, Cannon CP, Murphy SA, et al. Association between white blood cell count, epicardial blood flow, myocardial perfusion, and clinical outcomes in the setting of acute myocardial infarction: a thrombolysis in myocardial infarction 10 substudy. Circulation. 2000;102(19):2329-34. doi:10.1161/01.cir.102.19.2329.

34. Zhang Y, Li S, Guo YL, et al. Is monocyte to HDL ratio superior to monocyte count in predicting the cardiovascular outcomes: evidence from a large cohort of Chinese patients undergoing coronary angiography. Ann Med. 2016;48(5):305-12. doi:10.3109/07853890.2016.1168935.

35. Afari ME, Bhat T. Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update. Expert Rev Cardiovasc Ther. 2016;14(5):573-7. doi:10.1586/14779072.2016.1154788.

36. Bhat T, Teli S, Rijal J, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. 2013;11(1):55-9. doi:10.1586/erc.12.159.

37. Lee CD, Folsom AR, Nieto FJ, et al. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and white men and women: atherosclerosis risk in communities study. Am J Epidemiol. 2001;154(8):758-64. doi:10.1093/aje/154.8.758.

38. Balta S, Ozturk C. The platelet-lymphocyte ratio: A simple, inexpensive and rapid prognostic marker for cardiovascular events. Platelets. 2015;26(7):680-1. doi:10.3109/09537104.2014.979340.

39. Erturk M, Cakmak HA, Surgit O, et al. Predictive value of elevated neutrophil to lymphocyte ratio for long-term cardiovascular mortality in peripheral arterial occlusive disease. J Cardiol. 2014;64(5):371-6. doi:10.1016/j.jjcc.2014.02.019.

40. Bajari R, Tak S. Predictive prognostic value of neutrophil-lymphocytes ratio in acute coronary syndrome. Indian Heart J. 2017;69 Suppl 1(Suppl 1):S46-S50. doi:10.1016/j.ihj.2017.01.020.

41. Ueland T, Kleveland O, Michelsen AE, et al. Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction. Open Heart. 2018;5(2):e000765. doi:10.1136/openhrt-2017-000765.

42. Li S, Guo YL, Xu RX, et al. Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis. 2014;234(2):441-5. doi:10.1016/j.atherosclerosis.2014.04.001.

43. Chaulin AM, Duplyakov DV. PCSK9: modern views about biological role and possibilities of use as a diagnostic marker for cardiovascular diseases. Part 1. Cardiology: News, Opinions, Training. 2019;7(2):45-57. (In Russ.) doi:10.24411/2309-1908-2019-12005.

44. Arisoy A, Altunkas F, Karaman K, et al. Association of the Monocyte to HDL Cholesterol Ratio With Thrombus Burden in Patients With ST-Segment Elevation Myocardial Infarction. Clin Appl Thromb Hemost. 2017;23(8):992-7. doi:10.1177/1076029616663850.

45. Kivimaki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018;15(4):215-29. doi:10.1038/nrcardio.2017.189.

46. Azab B, Shah N, Akerman M, et al. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. J Thromb Thrombolysis. 2012;34(3):326-34. doi:10.1007/s11239-012-0718-6.

47. Gary T, Pichler M, Belaj K, et al. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. Plos One. 2013;8(7):e67688. doi:10.1371/journal.pone.0067688.

48. Inonu Koseoglu H, Pazarli AC, Kanbay A, et al. Monocyte Count/HDL Cholesterol Ratio and Cardiovascular Disease in Patients With Obstructive Sleep Apnea Syndrome: A Multicenter Study. Clin Appl Thromb Hemost. 2018;24(1):139-44. doi:10.1177/1076029616677803.